Cortina Asset Management LLC Acquires Shares of 580,503 Neos Therapeutics, Inc. (NEOS)
Cortina Asset Management LLC acquired a new position in Neos Therapeutics, Inc. (NASDAQ:NEOS) during the third quarter, according to its most recent filing with the SEC. The firm acquired 580,503 shares of the company’s stock, valued at approximately $5,312,000. Cortina Asset Management LLC owned about 2.12% of Neos Therapeutics as of its most recent filing with the SEC.
Several other hedge funds have also modified their holdings of NEOS. State of Wisconsin Investment Board bought a new stake in shares of Neos Therapeutics in the 2nd quarter worth approximately $102,000. OMERS ADMINISTRATION Corp bought a new stake in shares of Neos Therapeutics in the 2nd quarter worth approximately $110,000. Dynamic Technology Lab Private Ltd bought a new stake in shares of Neos Therapeutics in the 2nd quarter worth approximately $118,000. Tudor Investment Corp ET AL bought a new stake in shares of Neos Therapeutics in the 2nd quarter worth approximately $146,000. Finally, Rhumbline Advisers grew its position in shares of Neos Therapeutics by 13.6% in the 2nd quarter. Rhumbline Advisers now owns 20,409 shares of the company’s stock worth $149,000 after buying an additional 2,441 shares during the last quarter. Hedge funds and other institutional investors own 45.13% of the company’s stock.
A number of brokerages have recently weighed in on NEOS. Cantor Fitzgerald began coverage on Neos Therapeutics in a research report on Monday, July 31st. They issued an “overweight” rating and a $20.00 price objective on the stock. ValuEngine upgraded Neos Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 12th. Zacks Investment Research upgraded Neos Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, October 31st. Royal Bank Of Canada set a $12.00 price objective on Neos Therapeutics and gave the stock an “outperform” rating in a research report on Tuesday, August 8th. Finally, Cowen Inc reiterated a “buy” rating on shares of Neos Therapeutics in a research report on Thursday, October 26th. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $14.00.
Shares of Neos Therapeutics, Inc. (NEOS) opened at $9.75 on Friday. The company has a current ratio of 2.42, a quick ratio of 2.14 and a debt-to-equity ratio of 4.01. Neos Therapeutics, Inc. has a 1 year low of $4.85 and a 1 year high of $13.15.
Neos Therapeutics (NASDAQ:NEOS) last released its quarterly earnings results on Wednesday, November 8th. The company reported ($0.58) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.80) by $0.22. Neos Therapeutics had a negative return on equity of 551.26% and a negative net margin of 339.52%. The company had revenue of $6.70 million for the quarter. equities analysts predict that Neos Therapeutics, Inc. will post -2.87 earnings per share for the current year.
Neos Therapeutics Profile
Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).
Receive News & Ratings for Neos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.